US Patent Issued to ImmunityBio on July 22 for "Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors" (California Inventors)

ALEXANDRIA, Va., July 23 -- United States Patent no. 12,365,874, issued on July 22, was assigned to ImmunityBio Inc. (San Diego).

"Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors" was invented by John H. Lee (Culver City, Calif.), Laurent H. Boissel (Culver City, Calif.) and Hans G. Klingemann (Culver City, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are genetically modified NK cells expressing a chimeric antigen receptor targeting an EGFR superfamily receptor. The CAR can comprise an intracellular domain of FcEpsilonRIGamma and further recombinant proteins expressed by the genetically modified NK cells are CD16, autocrine growth stimulating cytokines, ...